Pharmacokinetic Study of a New Derivative of Sulfamethoxazole

Abstract

The study was aimed at determination of pharmacokinetic parameters of a previously synthesized salicylidine-sulfamethoxazole-Zn(II) monohydrate in normal humans. This new derivative of sulfamethoxazole was reported to be more active and less toxic than the parent drug by our group. 10 volunteers received a 200 mg dose of the drug orally. Blood samples were collected just before and after 0.16, 0.33, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0 and 8.0 h of administration of the drug. The plasma samples were analyzed for sulfamethoxazole by a new validated high performance liquid chromatography method having a suitable limit of quantification. The dose of each drug was well tolerated without any adverse effect. The maximum plasma sulfamethoxazole concentration was 280 μg L^− 1 at a t_max 1.30 h. This suggests a rapid onset effect of the complex as compared with the parent drug. The plasma half-life, clearance, and volume of distribution of sulfamethoxazole from salicylidine-sulfamethoxazole-Zn(II) monohydrate were 1.64 h, 0.24 L h^− 1 and 0.57 L kg^− 1 respectively. The elimination of sulfamethoxazole followed the first order kinetics with R²>0.984. The larger value of volume of distribution and clearance for the new derivative, as compared to that of the parent drug, show that the new derivative may exhibit prolonged antimicrobial effect with rapid clearance.

Key words

pharmacokinetics - salicylidine-sufamethoxazole-Zn(II) - sulfamethoxazole - zinc complex - HPLC

• References

• 1 Brown AG, Roberts SM. Recent Advances in the Chemistry of β-Lactam Antibiotics. The Royal Society of Chemistry; London: 1984
• 2 Iqbal MS, Bukhari IH, Arif M. Preparation, characterization and biological evaluation of copper (II) and zinc (II) complexes with Schiff bases derived from amoxicillin and cephalexin. App Organomet Chem 2005; 19: 864-869
• 3 Iqbal MS, Khan AH, Loothar BA et al. Effect of derivatization of sulfamethoxazole and trimethoprim with copper (II) and zinc (II) on their medicinal value. Med Chem Res 2009; 18: 31-42
• 4 Yang XL, Liu J, Yang L et al. Synthesis, characterization and susceptibility of bacteria of selenium dioxide complexes with drugs. Synth and React Inorg Metal-Organic Nano-Metal Chem 2005; 35 (10) 761-66
• 5 Sheela CD, Gomathi A, Ravichandran S et al. Studies of Schiff base complexes of salicylaldehyde with sulphamethoxazole and their antimicrobial activities. Pol J Chem 2006; 80: 1781-1787
• 6 Vinod P, Kamal K, John WA et al. Bioanalytical method validation-A revisit with a decade of progress. Pharm Res 2006; 17: 1551-1557
• 7 Campero RA, Escudero RB, Alvarez DDCV et al. Bioequivalence of two commercial preparations of trimethoprim/sulfamethoxazole: A randomized, single-dose, single-blind, crossover trial. Clin Therapeut 2007; 29 (02) 326-333
• 8 Brater DC. Pocket manual of drug use in clinical medicine. 3^rd Ed, Jaypee Brothers; India: 1991: 113